Predicting Cervical Lymph Node Metastasis Following Endoscopic Surgery in Superficial Head and Neck Carcinoma

Ryuichi Okabe1,2, Yushi Ueki1*, Riuko Ohashi1,3,4, Manabu Takeuchi5,6, Satoru Hashimoto5, Takeshi Takahashi5, Ryusuke Shodo1, Keisuke Yamazaki1, Hiroshi Matsuyma1,7, Hajime Umezu8, Shuji Terai5, Yoichi Ajioka3 and Arata Horii1

Background: Early detection of head and neck carcinoma (HNC) as superficial HNC (SHNC) identified using recently developed optical techniques, such as magnifying endoscopy and narrow-band imaging (NBI), in combination with endoscopic surgeries enables minimally invasive treatment with favorable outcomes for HNC. This study aimed to identify the predictive factors for the rare but important clinical issue of SHNC, namely cervical lymph node metastasis (CLNM), following endoscopic resection.

Methods: Sixty-nine patients with SHNC who underwent endoscopic resection were enrolled in the study. Clinical data, preoperative endoscopic findings, pathological findings, and treatment outcomes were retrospectively reviewed. Because the pharyngeal mucosa lacks the muscularis mucosa, we measured tumor thickness in permanent pathology as an alternative to the depth of invasion. Correlations with the occurrence of CLNM were statistically examined.

Results: The 5-year disease-specific survival rate was 100%. Of 69 patients, 3 (4.3%) developed CLNM. All had subepithelial but not epithelial tumors. The 0-IIa type in the macroscopic findings, type B2/B3 vessels in narrow-band imaging, tumors ≥ pathological stage T2, lymphatic invasion, positive surgical margins, and tumor thickness > 1,000 µm showed significant correlations with CLNM following endoscopic resection. Furthermore, the classification of type B vessels was significantly associated with tumor thickness.

Conclusion: The treatment outcomes following endoscopic resection for SHNC were favorable. The risk of CLNM following endoscopic resection in SHNC can be predicted by...
INTRODUCTION

Head and neck carcinoma (HNC), particularly laryngeal or pharyngeal carcinoma, is often found as an advanced-stage disease (1). Therefore, invasive interventions, including laryngectomy or concurrent chemoradiotherapy, are needed for curative therapy. This usually results in a swallowing disturbance or loss of voice, aggravating the quality of life (1). Developed optical techniques such as narrow-band imaging (NBI) and magnifying endoscopy facilitate the detection of HNC at an early phase, i.e., superficial HNC (SHNC) (2).

SHNC is defined as cancer involving the epithelium/subepithelial layer but not the muscularis propria irrespective of the presence of cervical lymph node metastasis (CLNM) (Figure 1) (3–5). The treatment strategy for SHNC follows a plan similar to that of superficial esophageal squamous cell carcinoma (6). Minimally invasive transoral endoscopic resection such as endomucosal resection, endoscopic submucosal dissection, and endoscopic laryngopharyngeal surgery but not chemoradiotherapy or extensive surgery may be a suitable and sufficient treatment for SHNC as well as superficial esophageal squamous cell carcinoma. Indeed, it achieves a favorable outcome and well-maintained postoperative functions (7). However, CLNM can occur in 2–19.4% of SHNC cases (8–12), which, in turn, is a clinical issue in the management of SHNC.

In the treatment of superficial esophageal squamous cell carcinoma, the incidence of lymph node metastasis depends on the depth of tumor invasion: 0–9.1% in Tis (epithelium [EP]) or T1a tumor (lamina propria mucosa [LPM] and muscularis mucosa [MM]) and 15.4–44.1% in T1b tumor (submucosa [SM]1–SM3) (Figure 1) (13). Thus, according to the National Comprehensive Cancer Network guidelines for esophageal carcinoma (14), endoscopic resection is recommended as initial definitive therapy for Tis and T1a superficial esophageal carcinoma, whereas an adjuvant therapy is recommended for T1b esophageal carcinoma due to the high risk of lymph node metastasis. Therefore, an accurate evaluation of the depth of invasion, which separates T1b from Tis/T1a tumor, is essential to determine the treatment strategy for superficial esophageal squamous cell carcinoma. For this purpose, NBI under magnifying endoscopy, which assesses the microvessel irregularity of the tumor surface, is useful to predict the depth of invasion (15).

In contrast to the esophagus, the pharyngeal mucosa lacks the MM, a key structure for determining the depth of invasion that predicts lymph node metastasis in superficial esophageal squamous cell carcinoma (Figure 1). Therefore, SHNC is classified only into two levels, namely EP and subepithelium (SEP) (Figure 1). The Japanese Society for Head and Neck Cancer recommends applying tumor thickness as an alternative to the depth of invasion to assess the risk of vessel invasion (3). Several reports have shed light on the high risk of CLNM for tumors with >1,000 µm thickness (8, 12, 16). However, they did not conduct statistical comparisons with non-CLNM cases. Moreover, previous reports included mixed CLNM cases with both synchronous and metachronous metastases even though the risk factors for metachronous CLNM are more important than those for synchronous CLNM in terms of prognosis. The aims of the present study were to identify the predictive factors for metachronous CLNM following endoscopic resection of SHNC among several preoperative endoscopic and postoperative pathological findings.

PATIENTS AND METHODS

Patients

This study was approved by the appropriate institutional review board (No. 2538) and was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Our retrospective cohort study included 69 patients with SHNC who were treated with endoscopic resection between 2007 and 2017. Patients who had received prior radiotherapy on the head and neck or had cervical lymph node metastasis at the initial diagnosis were excluded from the study. Written informed consent was obtained from all study participants.

Assessment of Endoscopic Findings

We classified the endoscopic findings of the tumor type and microvessel irregularity according to the Japan Esophageal Society classification (17). Superficial cancer was categorized as type 0, which was further classified into the following stages: 0-I (protruding type), 0-II (flat type), and 0-III (excavated type). Types 0-I and 0-II were further subclassified into 0-Ip (pedunculated type), 0-Ia (sessile [broad based] type), 0-IIa (slightly elevated type), 0-IIb (flat type), and 0-IIc (slightly depressed type) (18). Furthermore, microvessel irregularity under NBI was classified into type B1, B2, and B3 vessels (Figures 2A–C). Avascular area (AVA) was defined as a low or no vascularity area surrounded by stretched irregular vessels, such as B2 or B3 vessels (Figures 2D–F) (1).

Analysis of Predictive Factors

We extracted the clinical data (e.g., age, sex, primary tumor site, synchronous or metachronous carcinoma), treatment outcome (i.e., disease-free survival and overall survival), and endoscopic findings (i.e., macroscopic findings and microvessel irregularity) from the electronic clinical records. A gastroenterologist (SH...
FIGURE 1 | Comparison of the depth of invasion between superficial esophageal carcinoma and superficial head and neck carcinoma. Superficial carcinoma does not invade the muscularis propria. Tis is an in situ carcinoma. According to the presence of invasion over the muscularis mucosa, T1 superficial esophageal squamous cell carcinoma is classified into two categories, namely T1a (LPM, MM) and T1b (SM1, SM2, SM3). Superficial head and neck carcinoma is divided into two subgroups—EP (Tis) and SEP tumors—due to the lack of muscularis mucosa. The incidence of lymph node metastasis is different between Tis/T1a and T1b in superficial esophageal carcinoma. LN, lymph node; EP, epithelium; LPM, lamina propria mucosa; MM, muscularis mucosa; SM, submucosa; MP, muscularis propria; SEP, subepithelium.

FIGURE 2 | Representative images of superficial head and neck cancer according to the classification of microvessel irregularity under narrow band imaging. Type B vessels show the following four characteristics: weaving, dilation, irregular caliber, and different shapes. They are further subdivided into B1–B3 vessels. Avascular area (AVA) is defined as a low or no vascularity area, surrounded by stretched irregular vessels, such as B2 or B3 vessels. The diameter of AVA is positively correlated with the depth of invasion. Thus, AVA is further categorized according to its diameter. (A) Type B1 vessels have a loop-like formation, which appears as dot-like microvessels (e.g., a brownish area). (B) Type B2 vessels lack the loop-like formation (white circle). (C) Type B3 vessels have highly dilated abnormal vessels (white arrows). (D) Small-sized AVA (<0.5 mm in diameter). (E) Middle-sized AVA (0.5≤<3 mm), and (F) large-sized AVA ≥3 mm.

and MT) evaluated the endoscopic findings (macroscopic type and microvessel irregularity). All histological slides were reviewed by three pathologists (RO, HU, and YA), who were blinded to the clinical data. The pathological T stage was determined according to the 8th edition of the American Joint Committee on Cancer’s cancer staging system (19). Additionally, we classified the depth of invasion in SHNC as either EP (tumor located in the epithelium, equivalent to carcinoma in situ) or SEP (tumor involving the subepithelial layer). Tumor thickness, defined as the distance from the tumor surface to the deepest point of tumor invasion (3, 20, 21), was measured in the SEP tumors.
TABLE 1 | Patients' background.

| Age (median, years) | 36–86 (70) |
|---------------------|------------|
| Sex (male:female)   | 63:6       |
| Primary tumor site  |            |
| Hypopharynx         |            |
| Pyriform sinus      | 48 69.6%   |
| Postcricoid         | 2 2.9%     |
| Posterior wall      | 7 10.1%    |
| Oropharynx          |            |
| Larynx              | 1 1.4%     |
| Synchronous or metachronous cancer* | 13 18.8% |
| Head and Neck       | 13 18.8%   |
| Esophagus           | 31 44.9%   |
| Gastric             | 9 13.0%    |
| Other               | 10 14.5%   |

*Data is duplicated.

Statistical Analyses
December 2017 was the data cut-off date for the analyses of disease-specific survival and overall survival. The median follow-up period for the 69 patients was 44 months (range, 2–144 months). Survival time was estimated using the Kaplan–Meier method. Comparisons of the CLNM-free survival between the groups were estimated using the log-rank test and Cox regression with Firth’s penalized likelihood. Further, statistical evaluation of the associations between two categorical variables was performed using Fisher’s exact test. All statistical tests were two-sided; a p < 0.05 was regarded as statistically significant. All statistical analyses were performed using R version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria) and EZR version 1.37 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) (22).

RESULTS

Patients’ Clinical Data
Table 1 summarizes the demographic data of the patients. The median age was 70 years (range, 36–86 years), and 63 patients (91.3%) were men. The primary site was the hypopharynx in 57 lesions (82.6%), oropharynx in 11 lesions (15.9%), and larynx in 1 lesion (1.4%). No patients had synchronous SHNC. The incidence of synchronous and metachronous carcinoma was 18.8% (13/69) in the head and neck (not SHNC), 44.9% (31/69) in the esophagus, 13.0% (9/69) in the stomach, and 14.5% (10/69) in other areas, with overlaps.

Endoscopic and Pathological Findings
Table 2 shows the endoscopic and permanent pathological findings of SHNC. Type 0-IIb was the most common macroscopic type (45 patients, 65.2%). Type B1 was the most common microvessel irregularity (48 patients, 69.6%), followed by type B2 (16 patients, 23.2%) and type B3 (five patients, 7.2%). We identified AVA in 15 patients (21.7%). AVA was classified as small, middle, and large in eight (11.6%), five (7.2%), and two patients (2.9%), respectively (data not shown).

The pathological T stage was pTis in 37 patients (53.6%), pT1 in seven patients (10.1%), pT2 in 17 patients (24.6%), and pT3 in eight patients (11.6%). The depth of invasion was EP and SEP in 37 (53.6%) and 32 patients (46.4%), respectively. No tumors invaded the muscularis propria. Venous invasion was confirmed in only one patient (1.4%) while lymphatic invasion was confirmed in two patients (2.9%). The surgical margin was positive in 12 patients (17.4%) and indeterminable in 3 patients (4.3%). The median tumor width was 23 mm (3–65 mm), and the median thickness of SEP tumors was 1,225 (420–4,100) µm.

Treatment Outcomes
Endoscopic submucosal dissection, endoscopic laryngopharyngeal surgery, and transoral videolaryngoscopic surgery were performed on 62 (89.9%), 5 (7.2%), and 2 patients (2.9%), respectively. The 5-year disease-specific and overall survival rates were 100% and 74.9%, respectively. Thirteen
patients (18.8%) died of synchronous or metachronous cancer. No patient experienced local recurrence. However, 3 of 69 patients (4.3%) developed CLNM. The 5-year CLNM-free survival rate was 95.4%.

Endoscopic and Pathological Findings and Treatment Outcomes of Three Cases With CLNM

Figure 3 shows the preoperative endoscopic findings and postoperative pathological findings of all three patients with CLNM. Case 1 had a Type 0-IIa tumor on the left pyriform sinus (Figures 3A–C) with type B2 vessels, and tumor thickness was 3,600 µm (double-headed arrow). Case 2 had a Type 0-IIa tumor on the posterior wall of the left pyriform sinus with type B3 vessels (Figures 3D–F), and tumor thickness was 3,000 µm (double-headed arrow). Case 3 had a Type 0-IIa tumor on the posterior wall with observable type B2 vessels (Figures 3G–I), and tumor thickness was 1,900 µm (double-headed arrow).

All CLNMs occurred within a year of endoscopic resection, for which the patients underwent salvage therapy. We performed neck dissection followed by postoperative radiotherapy for two patients and concurrent chemoradiotherapy for one patient. All patients survived without recurrence or metastasis at the cutoff date.

Predictive Factors for CLNM

The log-rank test and Cox regression revealed an association between CLNM and the IIa macroscopic type (hazards ratio [HR], 32.85), B2 or B3 type vessels (HR, 15.402), pT2 or pT3 stage (HR, 13.163), positive lymphatic invasion (HR, 97.5), positive surgical margin (HR, 27.71), and >1,000 µm tumor thickness (HR, 16.213) (Table 3). All three cases with CLNM had SEP invasion. As shown in Table 4, tumor thickness shows a significant correlation with the classification of type B vessels (p = 0.018).

DISCUSSION

Treatment Outcomes

Previous studies have reported 100% 5-year disease-specific survival rates in patients who have undergone endoscopic resection for SHNC (1, 10, 11). The incidence of local recurrence in SHNC is reportedly 1.2–13% (8–10). Consistent with these reports, none of our patients died from SHNC, and the 5-year disease-specific survival rate was 100%. Furthermore, there was
no local recurrence. Different from disease-specific survivals, the 5-year overall survival rate was as low as 74.9% in this study. Thirteen patients died from synchronous or metachronous cancer in the upper aerodigestive tract known as “field cancerization” (23). It is suggested that endoscopic resection is a non-invasive and beneficial strategy for SHNC, while a careful exploration of metachronous as well as synchronous cancer is extremely important in patients with SHNC.

The incidence of synchronous and/or metachronous CLNM in SHNC is reportedly 2–19.4% (8–12). In the present study, CLNM after endoscopic resection occurred in 4.3% (3/69) of patients with SHNC and in 9.4% (3/32) of patients with SEP tumors. Despite being rare, CLNM can occur in SHNC following an endoscopic surgery, and its early detection would provide a less invasive salvage treatment for patients. A careful follow-up is particularly important for those at risk of CLNM following initial treatment. This, in turn, highlights the significance of identifying the predictive factors of CLNM following endoscopic surgery, which is discussed in the next paragraph.

**Predictive Factors for CLNM**

In clinical practice, predicting CLNM after endoscopic resection is equally important to detecting synchronous CLNM, as the latter is usually involved in planning the initial treatment strategy while the former affects follow-up after the initial treatment. Therefore, we focused on the correlation of CLNM following endoscopic surgery with possible predictors among the clinicopathological factors. Statistical tests showed that endoscopic findings, including macroscopic IIa type and type B2/B3 vessels, were significantly associated with CLNM following endoscopic resection. As pathological findings, ≥pT2 stage tumor, lymphatic invasion, positive surgical margin, and tumor thickness of ≥1,000 μm in SEP tumors showed significant association with CLNM following endoscopic resection (Table 3). Based on these findings, screening of high-risk CLNM cases by these preoperative endoscopic findings followed by confirmation using the above postoperative pathological findings may be an ideal assessment for a strict follow-up for possible CLNM following endoscopic resections.

**Table 3** | Log rank test and univariate Cox regression analyses of delayed lymph node metastasis-free survival.

|                          | Log rank test | Cox regression |
|--------------------------|---------------|----------------|
|                          | p value       | HR             | 95% CI | p value |
| Age                      |               |                |        |
| <70 vs. ≥70              | 0.516         | 2.173          | 0.197–23.97 | 0.527 |
| Location                 |               |                |        |
| Hypopharynx vs. others   | 0.405         | 1.619          | 0.157–217.752 | 0.735 |
| Macroscopic type         |               |                |        |
| Others vs. Ila           | <0.001*       | 32.85          | 3.178–4419.686 | 0.002† |
| Type B vessel            |               |                |        |
| B2/3 vs. B1              | 0.0102*       | 15.402         | 1.494–2070.895 | 0.019† |
| AVA                      |               |                |        |
| Present vs. absent       | 0.374         | 1.843          | 0.179–247.830 | 0.663† |
| Pathological Tstage      |               |                |        |
| T2/3 vs. Tis/1           | 0.018*        | 13.163         | 1.274–v1770.938 | 0.028† |
| Invasion                 |               |                |        |
| SEP vs. EP               | 0.052         | 8.853          | 0.858–1190.693 | 0.07† |
| Lymphatic invasion       |               |                |        |
| Present vs. absent       | <0.001*       | 97.5           | 5.201–14227.23 | 0.004† |
| Venous invasion present  | 0.827         | 8.986          | 0.067–92.686 | 0.283† |
| Surgical margin positive |               |                |        |
| Present vs. absent       | <0.001*       | 27.71          | 2.508–306.1 | 0.007† |
| Negative and indeterminable |             |                |        |
| Tumor thickness ≥1,000   | 0.008         | 16.213         | 1.572–2180.189 | 0.017† |

AVA, avascular area; SEP, subepithelial propria; EP, epithelium; HR, hazard ratio; CI, Confidence interval.

*Statistically significant.
†Firth’s correction was used because of quasi-complete separation; there was no event in one of the subgroups.

**Table 4** | Association between tumor thickness over 1,000μm and clinicopathological factors.

|                          | p value |
|--------------------------|---------|
| Age                      | 1       |
| <70 vs. ≥70              |         |
| Primary tumor site       | 1       |
| Hypopharynx vs. others   |         |
| Macroscopic type         | 0.155   |
| Others vs. Ila           |         |
| Type B vessel            | 0.0184* |
| B2/3 vs. B1              |         |
| AVA                      | 1       |
| Present vs. absent       |         |
| Pathological Tstage      | 0.648   |
| T2/3 vs. T1              |         |
| Lymphatic invasion       | 0.534   |
| Present vs. absent       |         |
| Venous invasion          | 1       |
| Present vs. absent       |         |
| Surgical margin          |         |
| Positive vs. negative and indeterminable | 1 |

AVA, avascular area. *Statistically significant.
i.e., EP and SEP in SHNC, so that EP/SEP may not be a sensitive correlate with CLNM (Table 3). As an alternative to the depth of invasion, several reports demonstrated that the tumor thickness correlated with CLNM, and tumor thickness of 1,000 μm was the threshold for risk of CLNM in SHNC (8, 9, 12). In these previous studies, however, statistical analyses of tumor thickness and CLNM were not fully conducted. Our results showed a statistically significant association between tumor thickness and CLNM (Table 3). As predictors for tumor thickness, Eguchi et al. have demonstrated a significant correlation between the classification of type B vessels and tumor thickness in superficial pharyngeal cancer (20). Katada et al. also have reported on the substantial correlation between the classification of type B vessels and synchronous lymph node metastasis/lymphatic invasion in superficial pharyngeal cancer (21). In the current study, among the parameters showing a significant correlation with CLNM, the classification of type B vessels was significantly associated with tumor thickness (Table 4). These results support the potential role of the classification of type B vessels in preoperative prediction for tumor thickness and risk of CLNM in SHNC, which may be useful for the selection of SHNC patients suitable for endoscopic resections plus watchful follow-up for possible CLNM.

A limitation of this study was the small number of CLNM-positive patients that were included; however, it should be noted that patients with SHNC rarely develop metachronous CLNM. Nonetheless, statistically significant predictors of CLNM may be obtained for comparison with non-CLNM cases as controls. Further prospective, large-scale observational studies are required to address the aforementioned drawbacks.

In conclusion, the treatment outcomes of SHNC following endoscopic surgery were favorable. However, CLNM following endoscopic resection was observed in 9.4% of patients with SEP tumors. Macroscopic type, classification of type B vessels under NBI, pathological T stage, lymphatic invasion, surgical margins, and tumor thickness were significantly associated with CLNM. Moreover, the classification of type B vessels had a significant correlation with tumor thickness as an alternative to the depth of invasion to assess the risk of CLNM. High-risk patients for CLNM can be predicted by the above preoperative endoscopic findings and postoperative pathological findings.

Among them, the classification of type B vessels, which correlated with tumor thickness and CLNM, might be a useful preoperative measure for the selection of SHNC patients suitable for endoscopic resections.

DATA AVAILABILITY STATEMENT

The original data presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board of the Niigata University Hospital (No. 2538). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YU had complete access to the data and takes responsibility for its integrity, and the accuracy of the data analysis. ROK, YU, and AH: concept and design. ROK, YU, ROH, MT, SH, TT, RS, KY, HM, HU, ST, and YA: acquisition and analysis or interpretation of data. ROK, YU, ROH, and AH: drafting of the manuscript. ROK, YU, ROH: statistical analysis. YU, ROH, MT, SH, TT, RS, KY, and HM: administrative and technical or material support. AH: supervision. All authors: critical revision of the manuscript for important intellectual content.

FUNDING

This study was supported by the Japan Society for Promotion of Sciences (JSPS) Grant in Aid for Scientific Research (C) #19K09884 to ROK.

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.com) for English language editing.

REFERENCES

1. Tateya I, Shiotani A, Satou Y, Tomifuku M, Morita S, Muto M, et al. Transoral surgery for laryngo-pharyngeal cancer – The paradigm shift of the head and neck cancer treatment. Auris Nasus Larynx. (2016) 43:21–32. doi: 10.1016/j.anl.2015.06.013

2. Yagishita A, Fuji S, Yano T, Kaneko K. Endoscopic findings using narrow-band imaging to distinguish between basal cell hyperplasia and carcinoma of the pharynx. Cancer Sci. (2014) 105:857–61. doi: 10.1111/cas.12440

3. Japan Society for Head and Neck Cancer. General Rules for Clinical Studies on Head and Neck Cancer. Tokyo, Japan: Kanehara Publishing Group (2012). pp. 58–65.

4. Di L, Fu KL, Xie R, Wu X, Li Y, Wu, H, et al. A modified endoscopic submucosal dissection for a superficial hypopharyngeal cancer: a case report and technical discussion. BMC cancer. (2017) 17:712. doi: 10.1186/s12885-017-3685-7

5. Jacques J, Bivory J, Lepilliez V, Rinaldi L, Saurin JC, Ponchon T, et al. Tunnel and clip endoscopic submucosal dissection of a pharyngeal superficial squamous cell carcinoma detected with narrow-band imaging. Endoscopy. (2017) 49:E48–50. doi: 10.1055/s-0042-122142

6. Kodama M, Kakegawa T. Treatment of superficial cancer of the esophagus: a summary of the responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery. (1998) 123:432–9. doi: 10.1016/S0039-6060(98)0165-5

7. Tateya I, Morita S, Muto M, Miyamoto S, Hayashi T, Funakoshi M, et al. Magnifying endoscope with NBI to predict the depth of invasion in laryngo-pharyngeal cancer. Laryngoscope. (2015) 125:1124–9. doi: 10.1002/lary.25035

8. Taniguchi M, Watanabe A, Tsuchie H, Tomiyama T, Fujita M, Hosokawa M, et al. Predictors of cervical lymph node involvement in patients with pharyngeal
cancer undergoing endoscopic mucosal resection. *Auris Nasus Larynx.* (2011) 38:710–7. doi: 10.1016/j.anl.2011.01.001
9. Kinjo Y, Nonaka S, Oda I, Abe S, Suzuki H, Yoshinaga S, et al. The short-term and long-term outcomes of the endoscopic resection for the superficial pharyngeal squamous cell carcinoma. *Endosc Int Open.* (2015) 3:E266–E273. doi: 10.1055/s-0034-1392094
10. Satake H, Yano T, Muto M, Minashi K, Yoda Y, Kojima T, et al. Clinical outcome after endoscopic resection for superficial pharyngeal squamous cell carcinoma invading the subepithelial layer. *Endoscopy.* (2015) 47:11–8. doi: 10.1055/s-0034-1378107
11. Watanabe A, Taniguchi M, Kimura Y, Hosokawa M, Ito S, Tsukamoto S, et al. Synopsis of transoral endoscopic laryngopharyngeal surgery for superficial pharyngeal cancers. *Endosc Int Open.* (2015) 3:E266–E273. doi: 10.1055/s-0034-1392094
12. Katada C, Okamoto T, Ichinoe M, Sakamoto Y, Kano K, Hosono H, et al. Prediction of lymph-node metastasis and lymphatic invasion of superficial pharyngeal cancer on narrow band imaging. *Head Neck.* (2019) 41:3970–5. doi: 10.1002/hed.25935
13. Makuuchi H. Endoscopic mucosal resection for early esophageal cancer: Indications and techniques. *Dig Endosc.* (1996) 8:175–9. doi: 10.1111/den.1996.8.3.175
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Esophageal and Esophagogastric Junction Cancers. Version 1. 2018. Available online at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf (accessed December 24, 2021).
15. Oyama T, Inoue H, Arima M, Momma K, Omori T, Ishihara R, et al. Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology: magnifying endoscopic classification of the Japanese esophageal society. *Esophagus.* (2017) 14:105–12. doi: 10.1007/s10388-016-0527-7
16. Ebisumoto K, Okami K, Sakai A, Ogura G, Sugimoto R, Saito K, et al. The potential risk of vessel infiltration and cervical lymph node metastasis in hypopharyngeal superficial squamous cell carcinoma: a retrospective observational study. *Acta Otolaryngol.* (2015) 135:729–35. doi: 10.3109/00016489.2015.1016186
17. Japan Esophageal Society. Japanese classification of esophageal cancer, the 11th edition: part I. *Esophagus.* (2017) 14:1–36. doi: 10.1007/s10388-016-0551-7
18. Oyama T, Momma K. A new classification of magnified endoscopy for superficial esophageal squamous cell carcinoma. *Esophagus.* (2011) 8:247–51.
19. Amin MB, Edge SB, Greene DM, Byrd DB, Brookland RK, Washington MK, et al., editors. *AJCC Cancer Staging Manual.* 8th ed. New York: Springer (2017). https://www.springer.com/gp/book/9783319406176
20. Eguchi K, Matsui T, Makai M, Sugimoto T. Prediction of the depth of invasion in superficial pharyngeal cancer: Microvessel morphological evaluation with narrowband imaging. *Head Neck.* (2019) 41:3970–5. doi: 10.1002/hed.25935
21. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant.* (2013) 48:452–8. doi: 10.1038/bmt.2012.244
22. Baba Y, Ishimoto T, Kurashige I, Iwatsuki M, Sakamoto Y, Yoshida N, et al. Epigenetic field cancerization in gastrointestinal cancers. *Cancer Lett.* (2016) 375:360–6. doi: 10.1016/j.canlet.2016.03.009

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Okabe, Ueki, Ohashi, Takesuchi, Hashimoto, Takahashi, Shodo, Yamazaki, Matsuyama, Umez, Terai, Ajioka and Horii. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). No use, distribution or reproduction is permitted which does not comply with these terms.